NCT02028455View on ClinicalTrials.gov

A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

167

Participants

Timeline

Start Date

February 11, 2014

Primary Completion Date

August 10, 2021

Study Completion Date

July 31, 2036

Conditions
CD19+ Acute Leukemia
Interventions
BIOLOGICAL

Patient Derived CD19 specific CAR T cells also expressing an EGFRt

Defined Composition CD4 and CD8 T cells Lentivirally Transduced to Express a Second Generation 4-1BB:zeta CD19 CAR and EGFRt

Trial Locations (3)

90027

Children's Hospital Los Angeles, Los Angeles

94609

Children's Hospital Oakland, Oakland

98105

Seattle Children's Hospital, Seattle

All Listed Sponsors
lead

Seattle Children's Hospital

OTHER

NCT02028455 - A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia | Biotech Hunter | Biotech Hunter